MediWound Ltd. (MDWD)

NASDAQ: MDWD · Real-Time Price · USD
16.55
-0.05 (-0.30%)
Sep 3, 2025, 4:00 PM - Market closed
-0.30%
Market Cap180.21M
Revenue (ttm)19.86M
Net Income (ttm)-28.23M
Shares Out 10.88M
EPS (ttm)-2.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume153,684
Open16.61
Previous Close16.60
Day's Range16.29 - 16.73
52-Week Range14.14 - 22.51
Beta0.25
AnalystsStrong Buy
Price Target35.00 (+111.48%)
Earnings DateAug 14, 2025

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically ap... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 20, 2014
Employees 111
Stock Exchange NASDAQ
Ticker Symbol MDWD
Full Company Profile

Financial Performance

In 2024, MediWound's revenue was $20.22 million, an increase of 8.22% compared to the previous year's $18.69 million. Losses were -$30.22 million, 350.0% more than in 2023.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for MDWD stock is "Strong Buy." The 12-month stock price target is $35.0, which is an increase of 111.48% from the latest price.

Price Target
$35.0
(111.48% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

MediWound's NexoBrid ® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global lead...

2 days ago - GlobeNewsWire

MediWound Is A Buy Opportunity On The Dip

MediWound is a niche biotech with strong R&D, FDA-approved products, and a promising pipeline, but remains underfollowed and volatile. Despite weak current performance and negative metrics, the compan...

2 days ago - Seeking Alpha

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, ...

15 days ago - GlobeNewsWire

MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Barry J.

20 days ago - Seeking Alpha

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid ® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strate...

21 days ago - GlobeNewsWire

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

MediWound Announces New EscharEx ® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

22 days ago - GlobeNewsWire

MediWound to Report Second Quarter 2025 Financial Results

MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd.

4 weeks ago - GlobeNewsWire

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD) Q1 2025 Earnings Conference Call May 21, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Ofer Gonen - CEO Hani Luxenburg - CFO Barry Wolfenson - EVP of ...

3 months ago - Seeking Alpha

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

VALUE Phase III trial of EscharEx ® in venous leg ulcers advancing as planned NexoBrid ® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of ...

3 months ago - GlobeNewsWire

MediWound Ltd.: Undervalued High-Growth Potential

I rate MediWound a buy due to strong revenue growth, a robust pipeline, and significant undervaluation with massive upside potential. NexoBrid's commercial success and orphan drug status drive revenue...

3 months ago - Seeking Alpha

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL® Post hoc analysis published in the peer-re...

4 months ago - GlobeNewsWire

MediWound to Report First Quarter 2025 Financial Results

Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time

4 months ago - GlobeNewsWire

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL ® , and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study ...

4 months ago - GlobeNewsWire

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chie...

6 months ago - Seeking Alpha

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for ...

6 months ago - GlobeNewsWire

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its f...

6 months ago - GlobeNewsWire

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burns NexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, I...

6 months ago - GlobeNewsWire

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Office...

6 months ago - GlobeNewsWire

MediWound to launch Phase III trial for venous leg ulcers

MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.

7 months ago - Reuters

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Phase III trial to assess the efficacy and safety of EscharEx ® for debridement and facilitation of active wound closure

7 months ago - GlobeNewsWire

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD) Q3 2024 Earnings Conference Call November 26, 2024 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - ...

10 months ago - Seeking Alpha

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC F...

10 months ago - GlobeNewsWire

MediWound Is A Healthy Investment

MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles, ...

11 months ago - Seeking Alpha

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes

11 months ago - GlobeNewsWire

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective...

1 year ago - GlobeNewsWire